# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Press Conference
- Reuters
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new...
- Reuters
- Reuters
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer ou...
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $25 ...
JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:NVAX) with a Underweight and raises the price target from $8 to $9.